Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Polyzos A, Malamos N, Boukovinas I, Adamou A, Ziras N, Kalbakis K, Kakolyris S, Syrigos K, Papakotoulas P, Kouroussis C, Karvounis N, Vamvakas L, Christophyllakis C, Athanasiadis A, Varthalitis I, Georgoulias V, Mavroudis D. Polyzos A, et al. Among authors: varthalitis i. Breast Cancer Res Treat. 2010 Jan;119(1):95-104. doi: 10.1007/s10549-009-0468-0. Epub 2009 Jul 28. Breast Cancer Res Treat. 2010. PMID: 19636702 Clinical Trial.
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Mavroudis D, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulias V; Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG). Mavroudis D, et al. Among authors: varthalitis i. Oncology. 2004;67(3-4):250-6. doi: 10.1159/000081325. Oncology. 2004. PMID: 15557786 Clinical Trial.
Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan.
Ziras N, Potamianou A, Varthalitis I, Syrigos K, Tsousis S, Boukovinas I, Tselepatiotis E, Christofillakis C, Georgoulias V. Ziras N, et al. Among authors: varthalitis i. Oncology. 2006;70(2):106-14. doi: 10.1159/000092956. Epub 2006 Apr 25. Oncology. 2006. PMID: 16645323 Clinical Trial.
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Georgoulias V, Androulakis N, Kotsakis A, Hatzidaki D, Syrigos K, Polyzos A, Agelidou A, Varthalitis I, Ziras N, Agelidou M, Chandrinos V, Boukovinas I, Geroyianni A, Vamvakas L, Mavroudis D. Georgoulias V, et al. Among authors: varthalitis i. Lung Cancer. 2008 Jan;59(1):57-63. doi: 10.1016/j.lungcan.2007.07.021. Epub 2007 Aug 31. Lung Cancer. 2008. PMID: 17765354 Clinical Trial.
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.
Briasoulis E, Fountzilas G, Bamias A, Dimopoulos MA, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N. Briasoulis E, et al. Among authors: varthalitis i. Cancer Chemother Pharmacol. 2008 Jul;62(2):277-84. doi: 10.1007/s00280-007-0604-7. Epub 2007 Sep 28. Cancer Chemother Pharmacol. 2008. PMID: 17901952 Clinical Trial.
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, Dimopoulos AM; Hellenic Cooperative Oncology Group. Fountzilas G, et al. Among authors: varthalitis i. Ann Oncol. 2008 May;19(5):853-60. doi: 10.1093/annonc/mdm539. Epub 2007 Nov 27. Ann Oncol. 2008. PMID: 18042835 Free article. Clinical Trial.
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
Kakolyris S, Souglakos J, Polyzos A, Ardavanis A, Ziras N, Athanasiadis A, Varthalitis I, Amarantidis K, Tsousis S, Vamvakas L, Vardakis N, Georgoulias V; Hellenic Oncology Research Group. Kakolyris S, et al. Among authors: varthalitis i. Oncology. 2008;74(1-2):31-6. doi: 10.1159/000138977. Epub 2008 Jun 10. Oncology. 2008. PMID: 18544957 Clinical Trial.
A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
Pallis AG, Agelidou A, Agelaki S, Varthalitis I, Pavlakou G, Gerogianni A, Papakotoulas P, Rapti A, Chandrinos V, Christophyllakis C, Georgoulias V. Pallis AG, et al. Among authors: varthalitis i. Lung Cancer. 2009 Aug;65(2):187-91. doi: 10.1016/j.lungcan.2008.11.002. Epub 2008 Dec 18. Lung Cancer. 2009. PMID: 19100647 Clinical Trial.
56 results